CHLA/USC Cell Therapy Program Seminar Series – Jordan Gauthier: Advancing CAR T-cell therapy for high-risk B-NHL

Date(s) - October 6, 2022
12:00 pm - 1:00 pm

Learn more about: Second-line (2L) standard-of-care (SOC) for large B-cell lymphoma (LBCL) CD19 CAR-T for relapsed/refractory (R/R) LBCL (>2L) Impact of the CD19 CAR product on outcomes of R/R LBCL CD19 CAR-T versus SOC for 2L high-risk LBCL

Speaker: Jordan Gauthier, MD, MSC
University of Washington School of Medicine 

This is an online event. Please RSVP KDsDat3_Bsoanx4sLO